AXL-selective TKIs have shown promise in preclinical models, particularly in combination with targeted BCR-ABL and FLT3 inhibition in CML and AML, respectively, and clinical trials are currently underway combining AXL inhibition with standard chemotherapy in AML. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.